Massmutual Trust Co. FSB ADV Has $51,000 Stake in Insulet Co. (NASDAQ:PODD)

Massmutual Trust Co. FSB ADV lifted its stake in shares of Insulet Co. (NASDAQ:PODD) by 159.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 254 shares of the medical instruments supplier’s stock after buying an additional 156 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Insulet were worth $51,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. bought a new position in Insulet during the 4th quarter valued at $34,000. Sunbelt Securities Inc. bought a new position in Insulet during the 1st quarter valued at $29,000. Jones Financial Companies Lllp bought a new position in Insulet during the 4th quarter valued at $40,000. Lindbrook Capital LLC lifted its stake in Insulet by 64.1% during the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after acquiring an additional 75 shares in the last quarter. Finally, Turtle Creek Wealth Advisors LLC bought a new position in Insulet during the 4th quarter valued at $43,000.

Insulet Trading Up 3.0 %

NASDAQ PODD opened at $196.35 on Wednesday. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $265.69. The stock has a market cap of $13.75 billion, a P/E ratio of 59.50, a P/E/G ratio of 3.55 and a beta of 1.16. The stock’s fifty day moving average price is $195.32 and its 200-day moving average price is $184.05. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The firm had revenue of $441.70 million for the quarter, compared to analysts’ expectations of $424.05 million. During the same period in the prior year, the firm posted $0.23 earnings per share. The company’s quarterly revenue was up 23.3% on a year-over-year basis. As a group, equities analysts forecast that Insulet Co. will post 3.11 EPS for the current fiscal year.

Insider Transactions at Insulet

In other news, SVP Mark N. Field sold 1,500 shares of the stock in a transaction on Friday, June 14th. The stock was sold at an average price of $199.96, for a total value of $299,940.00. Following the sale, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at $2,574,485. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, SVP Mark N. Field sold 2,131 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.43, for a total transaction of $405,806.33. Following the sale, the senior vice president now directly owns 14,375 shares of the company’s stock, valued at $2,737,431.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Mark N. Field sold 1,500 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $199.96, for a total value of $299,940.00. Following the sale, the senior vice president now directly owns 12,875 shares in the company, valued at $2,574,485. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,931 shares of company stock valued at $2,636,286. Insiders own 0.47% of the company’s stock.

Analysts Set New Price Targets

PODD has been the topic of a number of research reports. Redburn Atlantic initiated coverage on Insulet in a research note on Thursday, May 30th. They issued a “buy” rating and a $235.00 price objective on the stock. Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective on the stock in a research note on Tuesday, May 7th. Raymond James lowered their price objective on Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research note on Friday, May 10th. OTR Global restated a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. Finally, Barclays lowered their price objective on Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a research note on Monday, May 13th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $239.18.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.